Get the Stockscreener App
8.43
8.47%
-0.78
After Hours:
8.70
0.27
+3.20%
Greenwich Lifesciences Inc stock is traded at $8.43, with a volume of 126.20K.
It is down -8.47% in the last 24 hours and down -22.73% over the past month.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
See More
Previous Close:
$9.21
Open:
$9.2
24h Volume:
126.20K
Relative Volume:
1.92
Market Cap:
$114.90M
Revenue:
-
Net Income/Loss:
$-8.89M
P/E Ratio:
-12.04
EPS:
-0.7
Net Cash Flow:
$-6.48M
1W Performance:
-13.89%
1M Performance:
-22.73%
6M Performance:
-15.62%
1Y Performance:
-37.28%
1-Day Range:
$8.43
$9.22
1-Week Range:
$8.43
$9.82
52-Week Range:
$8.06
$15.47
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Name
Greenwich Lifesciences Inc
Sector
Industry
Phone
203-434-3290
Address
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
8.43 | 125.53M | 0 | -8.89M | -6.48M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | Noble Capital Markets | Outperform |
| Sep-01-21 | Initiated | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Stock (GLSI) Latest News
Technical signs of recovery in Greenwich LifeSciences Inc.July 2025 PostEarnings & Free Real-Time Volume Trigger Notifications - newser.com
Published on: 2025-11-03 06:25:10 - newser.com
Greenwich LifeSciences Inc. stock daily chart insights2025 Big Picture & Technical Entry and Exit Alerts - newser.com
Key resistance and support levels for Greenwich LifeSciences Inc.2025 Geopolitical Influence & AI Enhanced Trading Signals - newser.com
Why Greenwich LifeSciences Inc. stock is seen as undervaluedEarnings Growth Report & Stepwise Swing Trade Plans - newser.com
Long term hold vs stop loss in Greenwich LifeSciences Inc.2025 Short Interest & Real-Time Chart Pattern Alerts - newser.com
When is the best time to exit Greenwich LifeSciences Inc.Market Risk Analysis & Smart Allocation Stock Reports - newser.com
Why Greenwich LifeSciences Inc. stock could benefit from AI revolutionJuly 2025 PostEarnings & Community Trade Idea Sharing Platform - newser.com
What recovery options are there for Greenwich LifeSciences Inc.July 2025 Closing Moves & Free Low Drawdown Momentum Trade Ideas - newser.com
How to interpret RSI for Greenwich LifeSciences Inc. stockEarnings Summary Report & Daily Oversold Stock Bounce Ideas - newser.com
Analyzing Greenwich LifeSciences Inc. with risk reward ratio chartsWeekly Gains Report & Weekly Market Pulse Alerts - newser.com
Full technical analysis of Greenwich LifeSciences Inc. stock2025 Major Catalysts & Smart Allocation Stock Tips - newser.com
Can Greenwich LifeSciences Inc. stock surprise with earnings upsideJuly 2025 Short Interest & Proven Capital Preservation Methods - newser.com
Applying sector rotation models to Greenwich LifeSciences Inc.July 2025 Reactions & Safe Capital Growth Plans - newser.com
Greenwich Lifesciences Advances Phase 3 Breast Cancer Study with GLSI-100 - TipRanks
Greenwich Lifesciences Inc Stock (GLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):